Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$6.04
-2.1%
$6.60
$5.02
$21.73
$1.19B-1.333.15 million shs2.36 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
+0.16%+2.83%-3.29%-46.95%-6.09%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$6.04
-2.1%
$6.60
$5.02
$21.73
$1.19B-1.333.15 million shs2.36 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
+0.16%+2.83%-3.29%-46.95%-6.09%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
2.87
Moderate Buy$26.41337.28% Upside

Current Analyst Ratings Breakdown

Latest WVE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Set Price Target$13.00
6/11/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Reiterated RatingBuy
5/20/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Boost Price TargetOverweight$13.00 ➝ $14.00
5/19/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Lower Price TargetBuy$18.00 ➝ $13.00
5/4/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Lower Price TargetBuy$30.00 ➝ $24.00
4/30/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Lower Price TargetBuy$52.00 ➝ $43.00
4/29/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Initiated CoverageBuy$50.00 ➝ $15.00
4/20/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Reiterated RatingSell (D-)
4/14/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Lower Price TargetBuy$30.00 ➝ $18.00
3/27/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Lower Price TargetBuy$38.00 ➝ $21.00
(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$42.73M27.20N/AN/A$3.10 per share1.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%7/30/2026 (Estimated)

Latest WVE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2026Q1 2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/A
11.26
11.26

Institutional Ownership

CompanyInstitutional Ownership
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
89.73%

Insider Ownership

CompanyInsider Ownership
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
24.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
240192.40 million145.65 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

WAVE Life Sciences stock logo

WAVE Life Sciences NASDAQ:WVE

$6.04 -0.13 (-2.11%)
Closing price 04:00 PM Eastern
Extended Trading
$6.07 +0.03 (+0.56%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.